Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate
Authors
Krogstad, Paul A.Wiznia, Andrew
Luzuriaga, Katherine
Danker, Wayne
Nielsen, Karin
Gersten, Merril J.
Kerr, Brad
Hendricks, Amy
Boczany, Barbara
Rosenberg, Martin
Jung, Denna
Spector, Stephen A.
Bryson, Yvonne J.
UMass Chan Affiliations
Department of PediatricsDocument Type
Journal ArticlePublication Date
1999-05-01Keywords
AdolescentAnti-HIV Agents
CD4 Lymphocyte Count
Child
Child, Preschool
Drug Therapy, Combination
Female
HIV Infections
HIV Protease Inhibitors
*HIV-1
Humans
Infant
Male
Nelfinavir
RNA, Viral
Reverse Transcriptase Inhibitors
Immunology and Infectious Disease
Pediatrics
Metadata
Show full item recordAbstract
An open-label study was conducted of nelfinavir mesylate, given with reverse transcriptase inhibitors to human immunodeficiency virus 1 (HIV-1)-infected infants and children 3 months to 13 years of age. Doses of nelfinavir mesylate of 20-30 mg/kg yielded drug exposures comparable to those seen in adults. The drug was well tolerated; mild diarrhea was the primary toxic effect observed. Seventy-one percent (39) of the 55 evaluable subjects had an initial decrease in plasma HIV-1 RNA, of at least 0.7 log10 copies/mL; suppression of plasma HIV-1 RNA levels to < 400 copies/mL was observed in 15. Children who began taking at least one new reverse transcriptase inhibitor near the time when nelfinavir mesylate was started, and those with a > or = 24% proportion of CD4 lymphocytes, had a greater chance of achieving and maintaining a decline in plasma HIV-1 RNA to < 400 copies/mL. Suppression of viremia was achieved in children as young as 3 months of age.Source
Clin Infect Dis. 1999 May;28(5):1109-18. Link to article on publisher's siteDOI
10.1086/514759Permanent Link to this Item
http://hdl.handle.net/20.500.14038/43468PubMed ID
10452644Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1086/514759